AMJ Global Technology (AMJT) 10-K 19 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Nov. 30, 2017	Apr. 18, 2018	May 31, 2017
Document And Entity Information
Entity Registrant Name	KANGE CORP.
Entity Central Index Key	1,593,773
Document Type	10-K
Document Period End Date	Nov. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--11-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	Yes
Is Entity's Reporting Status Current?	Yes
Entity Public Float			$ 228,000
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		14,167,524
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Nov. 30, 2017	Nov. 30, 2016
Current assets
Cash	$ 77	$ 155
Prepaid expenses	66,312
Total current assets	66,389	155
Long Term Other Assets - Investment	81,000
Total Assets	147,389	155
Current liabilities
Convertible notes payable to related parties, net of discount		52,081
Accounts payable		200
Due to related party	26,901	10,250
Accrued expenses	5,250
Accrued expenses - related party	1,000	6,029
Total current liabilities	33,151	68,560
Total Liabilities	33,151	68,560
Commitments and Contingencies
Stockholders' Equity (Deficit)
Common stock, $0.001 par value, 75,000,000 shares authorized, 14,167,524 and 10,570,000 shares issued and outstanding, respectively	14,168	10,570
Additional paid-in capital	808,330	541,253
Accumulated deficit	(708,260)	(620,228)
Total Stockholders' Equity (Deficit)	114,238	(68,405)
Total Liabilities and Stockholders' Equity (Deficit)	$ 147,389	$ 155

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Nov. 30, 2017	Nov. 30, 2016
Stockholders' deficit
Common stock, Par value	$ 0.001	$ 0.001
Common stock, Authorized	75,000,000	75,000,000
Common stock, Issued	14,167,524	10,570,000
Common stock, Outstanding	14,167,524	10,570,000

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Statements Of Operations
Revenue
Operating expenses:
General and administrative	22,779	27,593
Consulting	57,688
Total operating expenses	80,467	27,593
Operating loss	(80,467)	(27,593)
Other income (expense):
Interest expense	(5,395)	(5,826)
Amortization of debt discounts	(2,170)	(49,713)
Total other income (expense)	(7,565)	(55,539)
Net loss before taxes	(88,032)	(83,132)
Provision for income taxes
Net loss	$ (88,032)	$ (83,132)
Net loss per share - basic and diluted	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding - basic and diluted	11,217,085	10,570,000

STATEMENTS OF STOCKHOLDERS' EQU

STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Nov. 30, 2015	$ 10,570	$ 515,065	$ (537,096)	$ (11,461)
Beginning Balance, Shares at Nov. 30, 2015	10,570,000
Beneficial conversion feature		26,188		26,188
Stock issued for conversion of debt, Amount
Net Loss			(83,132)	(83,132)
Ending Balance, Amount at Nov. 30, 2016	$ 10,570	541,253	(620,228)	(68,405)
Ending Balance, Shares at Nov. 30, 2016	10,570,000
Beneficial conversion feature
Stock issued for consulting services, Amount	$ 155	123,845		124,000
Stock issued for consulting services, Shares	155,000
Stock issued for conversion of debt, Amount	$ 3,284	62,391		65,675
Stock issued for conversion of debt, Shares	3,283,700
Stock purchase agreement, Amount	$ 159	80,841		81,000
Stock purchase agreement, Shares	158,824
Net Loss			(88,032)	(88,032)
Ending Balance, Amount at Nov. 30, 2017	$ 14,168	$ 808,330	$ (708,260)	$ 114,238
Ending Balance, Shares at Nov. 30, 2017	14,167,524

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Cash flows from operating activities:
Net loss	$ (88,032)	$ (83,132)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Amortization of debt discount	2,170	49,713
Issuance of common stock for services	57,688
Interest expense converted to common stock	5,395
Changes in operating assets and liabilities
Accounts payable	(200)	(5,632)
Accrued expenses	5,250
Accrued expenses to related party	1,000	2,525
Net cash used in operating activities	(16,729)	(36,526)
Cash flows from investing activities:
Net cash provided by investing activities
Cash flows from financing activities:
Proceeds from loan from related party	16,651	10,250
Proceeds from convertible note payable to relate party		26,188
Net cash provided by financing activities	16,651	36,438
Net Change in Cash	(78)	(88)
Cash, beginning of period	155	243
Cash, end of period	77	155
SUPPLEMENTARY DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Beneficial Conversion Feature		26,188
Stock issued for prepaid consulting services	66,312
Stock issued for acquisition of investment	81,000
Conversion of convertible debt & accrued interest to common stock	$ 65,675

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS	Organization Kange Corp. ("Kange," the "Company," "we," "us," or "our") was incorporated under the laws of the State of Nevada on August 16, 2013 (Inception). We are a development stage company developing mobile software products, for Apple and Android platforms, starting in Estonia and Europe, which is our initial intended market. Apple is a trademark of Apple Inc., and Android is a trademark of Alphabet Inc. During 2017, we began focusing on the intersection of technology and wholistic technology-based health treatments, we retained an advisor having substantial experience in the technology sector, we retained two former professional athletes to advise us regarding sports health issues and treatments, and we are currently providing services to a third party to formulate a treatment model to meet the needs of professional athletes that struggle and suffer with PTSD, the early onset of dementia and Alzheimer’s. The Company is currently evaluating future operations in the wholistic health industry. Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. The Company's year-end is November 30. Fair Value of Financial Instruments The Company measures its financial assets and liabilities in accordance with generally accepted accounting principles. For certain of our financial instruments, including cash, accounts payable, accrued expenses, and short-term loans the carrying amounts approximate fair value due to their short maturities. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company sustained net losses of $88,032 and used cash in operating activities of $16,729 for the year ended November 30, 2017. The Company had an accumulated deficit of $708,260, at November 30, 2017. These factors raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate revenues and its ability to continue receiving investment capital and loans from related parties to sustain its current level of operations. The Company is in the process of securing working capital from investors for common stock, convertible notes payable, and/or strategic partnerships. No assurance can be given that the Company will be successful in these efforts. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the valuation of beneficial conversion feature debt discounts, valuation of derivatives, valuation of share-based payments and the valuation allowance on deferred tax assets. Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders' equity as previously reported. Net Earnings (Loss) Per Share In accordance with ASC 260-10, "Earnings per Share," basic net earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted average number of common and dilutive common stock equivalent shares outstanding during the period. Effect of Recent Accounting Pronouncements The Company reviews new accounting pronouncements as issued. No new pronouncements had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these financial statements as presented and does not anticipate the need for any future restatement of these financial statements because of the retro-active application of any accounting pronouncements issued subsequent to November 30, 2017 through the date these financial statements were issued.

ASSIGNMENT OF CONTRACTUAL RIGHT

ASSIGNMENT OF CONTRACTUAL RIGHTS	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
NOTE 2 - ASSIGNMENT OF CONTRACTUAL RIGHTS	On November 9, 2015, in exchange for 5,000,000 shares of common stock of the Company, the Company was assigned by AMJ Global, LLC ("AMJ Global"), a company beneficially owned by Dr. Arthur Malone, Jr., the Company's chief executive officer and director, the contractual rights of AMJ Global pursuant to its agreements with Blabeey, Inc. ("Blabeey"), a mobile App designer focused on social media and messaging. The irrevocable assignment, transferred and conveyed in its entirety to the Company, all of AMJ Global's rights and obligations that are stipulated and set forth in every and all agreements between AMJ Global and Blabeey, including, but not limited to, the agreement between AMJ Global and Blabeey dated October 26, 2015, pursuant to which AMJ Global received the right to purchase Blabeey’s software-related assets for $20,000,000. The transaction was, due to the structure of the agreement, between entities under common control and therefore the amount of the historical cost of the assets, $471,672, was recorded as an expense as there is no fixed and determinable future value, and the expense was recorded as a loss on the acquisition of contractual rights.

CONVERTIBLE NOTES PAYABLE TO RE

CONVERTIBLE NOTES PAYABLE TO RELATED PARTIES, NET OF DISCOUNTS	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
NOTE 3 - CONVERTIBLE NOTES PAYABLE TO RELATED PARTIES, NET OF DISCOUNTS	Convertible notes to related parties, net of discounts November 30, 2017 November 30, 2016 Principal, Principal, Debt net of Debt net of Principal Discount Discounts Principal Discount Discounts AMJ Global, LLC (a) $ - $ - $ - $ 9,935 $ - $ 9,935 AMJ Global, LLC - - - 18,128 - 18,128 AMJ Global, LLC - - - 19,901 - 19,901 AMJ Global, LLC - - - 6,287 (2,170 ) 4,117 Total $ - $ - $ - $ 54,251 $ (2,170 ) $ 52,081 (a) Assigned from Victor Stepanov on March 15, 2016. On November 9, 2015, the Company executed a convertible promissory note with Victor Stepanov, the former chief executive officer and director of the Company, for $9,935, in exchange for accrued compensation pursuant to his employment agreement with the Company. On March 15, 2016, Mr. Stepanov assigned this convertible promissory note to AMJ Global, LLC ("AMJ Global"). The note bears interest at the rate of 12% per annum, which accrues monthly. The note matures on November 8, 2016. The note has a conversion feature of $0.02 per share. A beneficial conversion feature of $9,935 was recorded and accreted monthly from the issuance date of the note through maturity. On September 29, 2017, the note holder converted the entire principal balance of $9,935 into 496,750 shares of common stock in the Company. See Notes 5 and 6. On November 9, 2015, the Company executed a convertible promissory note with AMJ Global, a company which is beneficially owned by Dr. Arthur Malone, Jr., the chief executive officer and director of the Company, for $18,128. This note was created due to the assignment of the balance due to shareholder (see Note 5), which was assigned to AMJ Global on November 9, 2015. The note bears interest at the rate of 12% per annum, which accrues monthly. The note matures on November 8, 2016. The note has a conversion feature of $0.02 per share. A beneficial conversion feature of $18,128 was recorded and accreted monthly from the issuance date of the note through maturity. On September 29, 2017, the note holder converted the entire principal balance of $18,128 into 906,400 shares of common stock in the Company. On February 5, 2016, the Company executed a convertible promissory note with AMJ Global for $19,901. This note was in exchange for the payment of certain vendors of the Company. The note bears interest at the rate of 12% per annum, which accrues monthly. The note matures on February 4, 2017. The note has a conversion feature of $0.02 per share. A beneficial conversion feature of $19,901 was recorded and accreted monthly from the issuance date of the note through maturity. On September 29, 2017, the note holder converted the entire principal balance of $19,901 into 995,050 shares of common stock in the Company. On April 6, 2016, the Company executed a convertible promissory note with AMJ Global for $6,287. This note was in exchange for the payment of certain vendors of the Company. The note bears interest at the rate of 12% per annum, which accrues monthly. The note matures on April 6, 2017. The note has a conversion feature of $0.02 per share. A beneficial conversion feature of $6,287 was recorded and accreted monthly from the issuance date of the note through maturity. On September 29, 2017, the note holder converted the entire principal balance of $6,287 into 314,350 shares of common stock in the Company. On September 29, 2017, AMJ Global, holder of four convertible promissory notes listed above, converted accrued interest in the amount of $11,423 into 571,150 shares of common stock in the Company.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
NOTE 4 - COMMITMENTS AND CONTINGENCIES	Legal Matters From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of November 30, 2017, there were no pending or threatened lawsuits.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
NOTE 5 - RELATED PARTY TRANSACTIONS	In support of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances are considered temporary in nature and have not been formalized by a promissory note. On November 1, 2017, the Company entered into a one-year office lease agreement with AMJ Global Entertainment LLC, a related party controlled by the Company’s CEO and director, ending November 2, 2018. The location of the leased office space is 11724 Ventura Blvd Suite B, Studio City, California 91604.The lease states monthly rent due of $1,000. As of November 30, 2017, the Company has an accrued expense to related party balance of $1,000. On November 1, 2017, the Company executed a stock purchase agreement with AMJ Global Entertainment, LLC, a related party controlled by the Company’s CEO and director. See Note 6.

COMMON STOCK

COMMON STOCK	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
NOTE 6 - COMMON STOCK	Common Stock On November 27, 2017, the Company increased its authorized shares of common stock from 75,000,000 to 750,000,000, par value $0.001 per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights. In the year ended November 30, 2017, the Company issued 3,983,465 shares of common stock of which 3,283,700 shares were to a related party for the conversion of $54,252 of principal convertible debt and $11,423 of accrued interest. In the year ended November 30, 2017, the Company issued a total of 155,000 shares of common stock to five separate consultants pursuant to advisory board agreements. Three advisory board agreements were made effective on May 25, 2017 with terms of 15,000 shares each to be issued for one year of services to be rendered. Two advisory board agreements were made effective on October 1, 2017 with terms of 30,000 shares each to be issued for one year of services. The Company recorded the advisory agreements based on the closing stock price of the Company on the date of the executed agreement which resulted in a total combined value of $124,000. The Company recorded the uncompleted portion of the contract as prepaid expense in the amount $66,312 and the completed portion as consulting expense in the amount of $57,688. On November 1, 2017, the Company executed a stock purchase agreement (the “SPA”) with AMJ Global Entertainment, LLC, a related party and holder of 4,803,195 shares of common stock in Patient Access Solutions Inc., a Nevada corporation with ticker symbol “PASO”. Pursuant to the SPA, the Company issued 158,824 shares of common stock in exchange for 1,157,142 shares of Patient Access Solutions Inc. The shares of Patient Access Solutions Inc. had a carried forward basis cost of approximately $0.07 per share which resulted in an initial valuation of $81,000. The Company recorded a long term other investment asset of $81,000 which was valued at the carry-over basis of the related party. There were 14,167,524 shares of common stock issued and outstanding as of November 30, 2017.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
NOTE 7 - INCOME TAXES	The Company's tax expense differs from the "expected" tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of 21% to loss before taxes), as follows: For the Years Ended November 30, 2017 2016 Tax expense (benefit) at the statutory rate $ (4,784 ) $ (17,458 ) State income taxes, net of federal income tax benefit - - Non-deductible items - - Change in valuation allowance 4,784 17,458 Total $ - $ - The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities. The tax effect of significant components of the Company's deferred tax assets and liabilities at November 30, 2017 and 2016, respectively, are as follows: November 30, 2017 2016 Deferred tax assets $ 28,215 $ 23,432 Less: Deferred tax asset valuation allowance (28,215 ) (23,432 ) Total net deferred tax assets $ - - In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Because of the historical earnings history of the Company, the net deferred tax assets for 2017 and 2016 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $28,215 and $23,432 as of November 30, 2017 and 2016, respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Nov. 30, 2017
Notes to Financial Statements
NOTE 8 - SUBSEQUENT EVENTS	The Company has evaluated subsequent events from November 30, 2017 through the date the financial statements were available to be issued and has determined that there have been no subsequent events after November 30, 2017 for which disclosure is required.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Nov. 30, 2017
Summary Of Significant Accounting Policies Policies
Organization	Kange Corp. ("Kange," the "Company," "we," "us," or "our") was incorporated under the laws of the State of Nevada on August 16, 2013 (Inception). We are a development stage company developing mobile software products, for Apple and Android platforms, starting in Estonia and Europe, which is our initial intended market. Apple is a trademark of Apple Inc., and Android is a trademark of Alphabet Inc. During 2017, we began focusing on the intersection of technology and wholistic technology-based health treatments, we retained an advisor having substantial experience in the technology sector, we retained two former professional athletes to advise us regarding sports health issues and treatments, and we are currently providing services to a third party to formulate a treatment model to meet the needs of professional athletes that struggle and suffer with PTSD, the early onset of dementia and Alzheimer’s. The Company is currently evaluating future operations in the wholistic health industry.
Basis of Presentation	The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. The Company's year-end is November 30.
Fair Value of Financial Instruments	The Company measures its financial assets and liabilities in accordance with generally accepted accounting principles. For certain of our financial instruments, including cash, accounts payable, accrued expenses, and short-term loans the carrying amounts approximate fair value due to their short maturities.
Going Concern	The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company sustained net losses of $88,032 and used cash in operating activities of $16,729 for the year ended November 30, 2017. The Company had an accumulated deficit of $708,260, at November 30, 2017. These factors raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate revenues and its ability to continue receiving investment capital and loans from related parties to sustain its current level of operations. The Company is in the process of securing working capital from investors for common stock, convertible notes payable, and/or strategic partnerships. No assurance can be given that the Company will be successful in these efforts. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the valuation of beneficial conversion feature debt discounts, valuation of derivatives, valuation of share-based payments and the valuation allowance on deferred tax assets.
Reclassifications	Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders' equity as previously reported.
Net Earnings (Loss) Per Share	In accordance with ASC 260-10, "Earnings per Share," basic net earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted average number of common and dilutive common stock equivalent shares outstanding during the period.
Effect of Recent Accounting Pronouncements	The Company reviews new accounting pronouncements as issued. No new pronouncements had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these financial statements as presented and does not anticipate the need for any future restatement of these financial statements because of the retro-active application of any accounting pronouncements issued subsequent to November 30, 2017 through the date these financial statements were issued.

CONVERTIBLE NOTES PAYABLE TO 16

CONVERTIBLE NOTES PAYABLE TO RELATED PARTIES, NET OF DISCOUNTS (Tables)	12 Months Ended
	Nov. 30, 2017
Convertible Notes Payable To Related Parties Net Of Discounts Tables
Convertible notes to related parties	November 30, 2017 November 30, 2016 Principal, Principal, Debt net of Debt net of Principal Discount Discounts Principal Discount Discounts AMJ Global, LLC (a) $ - $ - $ - $ 9,935 $ - $ 9,935 AMJ Global, LLC - - - 18,128 - 18,128 AMJ Global, LLC - - - 19,901 - 19,901 AMJ Global, LLC - - - 6,287 (2,170 ) 4,117 Total $ - $ - $ - $ 54,251 $ (2,170 ) $ 52,081

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Nov. 30, 2017
Income Taxes Tables
Federal income tax expense	For the Years Ended November 30, 2017 2016 Tax expense (benefit) at the statutory rate $ (4,784 ) $ (17,458 ) State income taxes, net of federal income tax benefit - - Non-deductible items - - Change in valuation allowance 4,784 17,458 Total $ - $ -
Deferred tax assets and liabilities	November 30, 2017 2016 Deferred tax assets $ 28,215 $ 23,432 Less: Deferred tax asset valuation allowance (28,215 ) (23,432 ) Total net deferred tax assets $ - -

ORGANIZATION AND NATURE OF BU18

ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Organization And Nature Of Business Details Narrative
State of incorporation	State of Nevada
Date of incorporation	Aug. 16, 2013
Net loss	$ (88,032)	$ (83,132)
Net cash used in operating activities	(16,729)	(36,526)
Accumulated deficit	$ (708,260)	$ (620,228)

ASSIGNMENT OF CONTRACTUAL RIG19

ASSIGNMENT OF CONTRACTUAL RIGHTS (Details Narrative) - USD ($)	1 Months Ended
	Oct. 26, 2015	Nov. 09, 2015
Common stock shares exchanged		5,000,000
Historical cost of assets		$ 471,672
Blabeey’s [Member]
Purchase software-related assets	$ 20,000,000

CONVERTIBLE NOTES PAYABLE TO 20

CONVERTIBLE NOTES PAYABLE TO RELATED PARTIES, NET OF DISCOUNTS (Details) - USD ($)	Nov. 30, 2017	Nov. 30, 2016
Principal		$ 54,251
Debt Discount		(2,170)
Principal, net of discount		52,081
AMJ Global LLC (a) [Member]
Principal		9,935
Debt Discount
Principal, net of discount		9,935
AMJ Global LLC One [Member]
Principal		18,128
Debt Discount
Principal, net of discount		18,128
AMJ Global LLC Two [Member]
Principal		19,901
Debt Discount
Principal, net of discount		19,901
AMJ Global LLC Three [Member]
Principal		6,287
Debt Discount		(2,170)
Principal, net of discount		$ 4,117

CONVERTIBLE NOTES PAYABLE TO 21

CONVERTIBLE NOTES PAYABLE TO RELATED PARTIES, NET OF DISCOUNTS (Details Narrative) - USD ($)	Apr. 06, 2016	Feb. 05, 2016	Nov. 09, 2015	Sep. 29, 2017	Nov. 30, 2017	Nov. 30, 2016
Beneficial conversion feature recorded					$ (2,170)	$ (49,713)
AMJ Global LLC Four [Member]
Debt conversion converted shares				571,150
Debt conversion converted principle amount				$ 11,423
AMJ Global LLC Three [Member]
Convertible notes payable	$ 6,287
Interest rate	12.00%
Maturity date	Apr. 6, 2017
Conversion price per share					$ 0.02
Beneficial conversion feature recorded					$ 6,287
Debt conversion converted shares				314,350
Debt conversion converted principle amount				$ 6,287
AMJ Global LLC Two [Member]
Convertible notes payable		$ 19,901
Interest rate		12.00%
Maturity date		Feb. 4, 2017
Conversion price per share					$ 0.02
Beneficial conversion feature recorded					$ 19,901
Debt conversion converted shares				995,050
Debt conversion converted principle amount				$ 19,901
AMJ Global LLC One [Member]
Convertible notes payable			$ 18,128
Interest rate			12.00%
Maturity date			Nov. 8, 2016
Conversion price per share					$ 0.02
Beneficial conversion feature recorded					$ 18,128
Debt conversion converted shares				906,400
Debt conversion converted principle amount				$ 18,128
AMJ Global LLC (a) [Member]
Convertible notes payable			$ 9,935
Interest rate			12.00%
Maturity date			Nov. 8, 2016
Conversion price per share					$ 0.02
Beneficial conversion feature recorded					$ 9,935
Debt conversion converted shares				496,750
Debt conversion converted principle amount				$ 9,935

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Accrued expenses - related party	$ 1,000	$ 6,029
AMJ Global [Member] | Lease Agreements [Member]
Due to monthly rent	$ 1,000

COMMON STOCK (Details Narrative

COMMON STOCK (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Nov. 27, 2017	Sep. 29, 2017	May 25, 2017	Nov. 30, 2017	Nov. 30, 2016	Nov. 01, 2017
Common stock, Authorized				75,000,000	75,000,000
Common stock, Par value				$ 0.001	$ 0.001
Common stock, Issued				14,167,524	10,570,000
Common stock, Outstanding				14,167,524	10,570,000
Number of separate consultants				five
Consulting expense				$ 57,688
Prepaid expense				$ 66,312
Patient Access Solutions Inc [Member]
Common stock, Issued						544,765
Exchange of common stock shares						1,157,142
Basis cost						$ 0.07
Exchange common stock value						$ 81,000
Long term other investment						$ 81,000
AMJ Global LLC (a) [Member]
Debt conversion converted principle amount		$ 9,935
Common stock shares issued related party						4,803,195
Common Stock
Increase of common stock authorized shares description	The Company increased its authorized shares of common stock from 75,000,000 to 750,000,000.
Shares issued				3,983,465
Stock issued for consulting services, Shares				155,000
Stock issued for consulting services, Amount				$ 124,000
Stock issued for conversion of debt, Shares				3,283,700
Debt conversion converted principle amount				$ 54,252
Accrued interest				$ 11,423
Stock purchase agreement shares				158,824
Advisory board agreements Two [Member]
Shares issued for services with terms			15,000
Advisory board agreements Two [Member] | October 1, 2017 [Member]
Shares issued for services with terms				30,000
Advisory board agreements One [Member]
Shares issued for services with terms			15,000
Advisory board agreements One [Member] | October 1, 2017 [Member]
Shares issued for services with terms				30,000
Advisory board agreements Three [Member]
Shares issued for services with terms			15,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Income Taxes Details
Tax expense (benefit) at the statutory rate	$ (4,784)	$ (17,458)
State income taxes, net of federal income tax benefit
Non-deductible items
Change in valuation allowance	4,784	17,458
Total

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Nov. 30, 2017	Nov. 30, 2016
Deferred tax assets:
Gross deferred tax assets	$ 28,215	$ 23,432
Less: Deferred tax asset valuation allowance	(28,215)	(23,432)
Total net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Nov. 30, 2017	Nov. 30, 2016
Income Taxes Details Narrative
Deferred tax asset valuation allowance	$ 28,215	$ 23,432
Valuation allowance	100.00%	100.00%
United States Federal tax rate	21.00%